Preclinical Development of 3BP-3940, a Fibroblast Activation Protein-Targeted Cyclic Peptide-Based Radiotheranostic for Imaging and Therapy.

lutetium Lu 177 rofapitide tetraxetan (AAA614) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/41571429

Aileen Höhne; Anne Bredenbeck; Christiane Smerling; Dirk Zboralski; Frank Osterkamp; Jan L von Hacht; Jan Ungewiss; Jeanette Libera-Körner; Matthias Paschke; Ulrich Reineke

Jan 23, 2026